Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to 546.15%.

  • Arcus Biosciences' EBITDA Margin fell 3274000.0% to 546.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 156.25%, marking a year-over-year decrease of 353400.0%. This contributed to the annual value of 127.91% for FY2024, which is 1626900.0% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' EBITDA Margin is 546.15%, which was down 3274000.0% from 5.0% recorded in Q2 2025.
  • Arcus Biosciences' EBITDA Margin's 5-year high stood at 78.45% during Q4 2021, with a 5-year trough of 824.66% in Q3 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 286.21% (2023), whereas its average is 339.52%.
  • Data for Arcus Biosciences' EBITDA Margin shows a peak YoY increase of 17804400bps (in 2021) and a maximum YoY decrease of -8273800bps (in 2021) over the last 5 years.
  • Over the past 5 years, Arcus Biosciences' EBITDA Margin (Quarter) stood at 78.45% in 2021, then crashed by -377bps to 217.65% in 2022, then crashed by -35bps to 293.55% in 2023, then tumbled by -35bps to 396.15% in 2024, then plummeted by -38bps to 546.15% in 2025.
  • Its EBITDA Margin stands at 546.15% for Q3 2025, versus 5.0% for Q2 2025 and 435.71% for Q1 2025.